Terry Moy

Terry Moy is a seasoned professional with extensive experience in screening biology and drug discovery. Currently serving as Sr. Director at Eli Lilly and Company since September 2025, Terry previously held multiple roles at Morphic Therapeutic from August 2015 to October 2025, including Director of Screening Biology, where duties involved leading groups supporting inflammatory bowel disease, fibrosis, and immuno-oncology projects. Early career includes roles at Cubist Pharmaceuticals focusing on biochemical assay development, and postdoctoral research at Broad Institute and Massachusetts General Hospital, where models for infection and anti-infective compound identification were developed. Educational credentials include a Ph.D. in Cell Biology from Harvard University and a B.A. in Molecular & Cellular Biology from Northwestern University.